Skip to content

Hydrocortisone/​Iodoquinol

    DEA Class; Rx

    Common Brand Names; Alcortin, Vytone

    • Corticosteroids, Topical

    Topical combination product containing steroid and antibacterial/antifungal agent
    Used for the treatment of skin infections

    Indicated for the treatment of contact dermatitis, atopic dermatitis, impetiginized eczema/ impetigo, nummular eczema, endogenous chronic infectious dermatitis, stasis dermatitis, pyoderma, nuchal eczema, chronic eczematoid otitis externa, acne urticata, localized or disseminated neurodermatitis, lichen simplex chronicus, anogenital pruritus (vulvus, scrotum, anus), folliculitis, bacterial dermatoses (declatoses), mycotic dermatoses (tinea capitis, tinea cruris, tinea corporis, tinea pedis), moniliasis, and intertrigo.

    Hypersensitivity

    Hepatic insufficienty

    Hydrocortisone

    • Skin atrophy

    • Striae

    • Acneform lesions

    • Pigmentation changes

    • HPA suppression (with higher potency used >2 wk)

    • Intracranial hypertension

    • Allergic contact dermatitis

    • Pruritus

    • Pustulation

    • Perioral dermatitis

    • Urticaria

    • Hypertrichosis

    • Leukoderma

    • Pigmentation changes

    Iodoquinol

    • Fever

    • Vertigo

    • Chills

    • Headache

    • Skin eruptions

    • Urticaria

    • Rash

    • Chills

    • Thyroid gland enlargement

    • Anal itching

    • Diarrhea

    • Nausea/vomiting

    • Peripheral neuropathy

    • Optic neuritis

    • Optic atrophy

    Chronic topical corticosteroid therapy may interfere with growth and development in children

    Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity

    External use only

    Use on extensive surface area or with occlusive dressing may increase systemic absorption and possibly toxicity

    Kaposi’s sarcoma reported with prolonged corticosteroid therapy

    Children may exhibit greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing’s syndrome due to larger skin surface area to body weight ratio

    Peripheral neuropathy may occur with prolonged use of high doses

    Optic neuritis may occur with prolonged use of high doses; avoid long term therapy

    Peripharal neuropathy may occur with prolonged use of high doses; avoid long term therapy

    Use caution in patients with thyroid disease

    Pregnancy Category: C

    Lactation: not known whether either drug applied topically enters breast milk; use caution

    Adults

    Maximum dosage information is not available.

    Geriatric

    Maximum dosage information is not available.

    Adolescents

    Maximum dosage information is not available.

    Children

    12 years and older: Maximum dosage information is not available.
    Less than 12 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Hydrocortisone acetate/iodoquinol

    Hydrocortisone/iodoquinol

    cream

    • 1%/1%
    • 2%/1%